McKesson Corp (MCK)

138.52
6.90 4.70
NYSE : Services
Prev Close 145.40
Open 142.68
Day Low/High 136.81 / 143.45
52 Wk Low/High 114.53 / 202.20
Volume 1.98M
Avg Volume 2.84M
Exchange NYSE
Shares Outstanding 226.09M
Market Cap 32.78B
EPS 9.80
P/E Ratio 16.27
Div & Yield 1.12 (0.80%)

Latest News

Uncertainties Making it Difficult for Investors in the Healthcare Sector, says Mizuho Analyst

Uncertainties Making it Difficult for Investors in the Healthcare Sector, says Mizuho Analyst

Since the election, big questions remain about investing in hospital and healthcare stocks, and the group will remain volatile according to Mizuho.

Andrew Left: Dump Mallinckrodt

Andrew Left: Dump Mallinckrodt

Famed short-seller says drugmaker at risk of a government crackdown.

Allergan, Macy's, Apple: Doug Kass' Views

Allergan, Macy's, Apple: Doug Kass' Views

Doug Kass shares his thoughts on closed-end municipal bond funds.

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

NKE, AGN, NFLX: Jim Cramer's Views

NKE, AGN, NFLX: Jim Cramer's Views

Cramer shares his views on price war victims. Nike, Allergan and Netflix are among the stocks discussed.

SBUX, AAPL, FB: Jim Cramer's Views

SBUX, AAPL, FB: Jim Cramer's Views

Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Health Care Sector Is Hurting

Cramer: Health Care Sector Is Hurting

You can't ignore the evidence.

ZBH's Big Unjustified Price Correction

ZBH's Big Unjustified Price Correction

Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.

Valeant Skyrockets on Rumored $10B Salix Sale

Valeant Skyrockets on Rumored $10B Salix Sale

Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.

Morning Movers: PFE, K, VRX, AEP

Morning Movers: PFE, K, VRX, AEP

Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.

Federal Probe Is No Halloween Treat for Valeant

Federal Probe Is No Halloween Treat for Valeant

Valeant shares drop as regulators investigate possible accounting fraud.

Valeant's Frightful Halloween

Valeant's Frightful Halloween

Troubled drug firm sheds 12% on fresh fraud news.

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.

Jim Cramer -- Health Care Could Be Susceptible to More Declines

Jim Cramer -- Health Care Could Be Susceptible to More Declines

Jim Cramer says health care stocks could see a temporary relief rally, but may be susceptible to further downside.

Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing

Trader's Daily Notebook: Uncertainty Leads to Assets' Repricing

I continue to believe downside risks far outweigh the risks of a near-term rally.

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

Stocks Under $10 Portfolio: Tax-Loss Selling Weighs on Indices

We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.

Jim Cramer's Top Takeaways: Amerisource Bergen, Avon And More

Jim Cramer's Top Takeaways: Amerisource Bergen, Avon And More

Drug wholesalers are battling it out, while Avon is looking better, says Jim Cramer.

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Cramer previews important earnings reports scheduled for the coming week.

McKesson Takes a Hit on Earnings, Drags Cardinal and Amerisource Bergan Down With It

McKesson Takes a Hit on Earnings, Drags Cardinal and Amerisource Bergan Down With It

McKesson Corp. (MCK) hit a 52-week low Friday, falling 23% Friday, hitting $114 per share before bouncing back to $124.57 before market's close.

McKesson Shares Plunge on Drug Price Cuts

McKesson Shares Plunge on Drug Price Cuts

Shares of the drug distributor were falling sharply Friday.

Stressed Out: Valeant Shareholders Flee on McKesson Warning

Stressed Out: Valeant Shareholders Flee on McKesson Warning

The drugmaker's shares were hammered Friday on news that the industry is slashing prices.

Trending Tickers: HSY, RCL, MCK, VRX

Trending Tickers: HSY, RCL, MCK, VRX

Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

Jim Cramer Explains Why Health Care Stocks are Getting Slammed on Wall Street Today

McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.

Jim Cramer: Healthcare Stocks in Crosshairs

Jim Cramer: Healthcare Stocks in Crosshairs

The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.